Cocrystal Pharma Reports Positive Phase 1 Study Results

The latest update is out from Cocrystal Pharma ( (COCP) ).

Cocrystal Pharma announced positive interim results from a Phase 1 study of its oral pan-viral protease inhibitor CDI-988, designed for the treatment of norovirus and coronavirus infections. The study demonstrated favorable safety and tolerability at doses up to 800 mg for 10 days, supporting further development and clinical trials. With norovirus outbreaks rising significantly, the potential of CDI-988 to address this unmet need could strengthen Cocrystal’s position in the antiviral market, as the company plans to commence a human challenge study in 2025.

More about Cocrystal Pharma

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics targeting the replication process of viruses such as influenza, coronaviruses, noroviruses, and hepatitis C. Utilizing unique structure-based technologies and expertise, Cocrystal aims to create first- and best-in-class antiviral drugs.

YTD Price Performance: -2.59%

Average Trading Volume: 42,998

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $24.42M

For a thorough assessment of COCP stock, go to TipRanks’ Stock Analysis page.